highly significantP = 0.01
While this difference was not significant for patients with SCC (HR 0.92; 95% CI, 0.81–1.04; P = 0.18), it was highly significant for patients with AC (HR 0.83; 95% CI, 0.71–0.95; P = 0.01). 3 However, in Japan, neoadjuvant chemotherapy for SCC with cisplatin/5-fluorouracil (FU) is still regarded as standard treatment and cannot be replaced by adjuvant chemotherapy with the same regimen. 4 Perioperative (neoadjuvant and adjuv